This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01454/identifier/wikipedia/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01454/identifier/pharmgkb/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01454/identifier/kegg-compound/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01454/identifier/pubchem-compound/
n15http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB01454/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB01454/identifier/drugbank/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01454/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01454/identifier/chebi/

Statements

Subject Item
n2:DB01454
rdf:type
n3:Drug
n3:description
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. [PubChem]
n3:generalReferences
# Freudenmann RW, Oxler F, Bernschneider-Reif S: The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16911722 # Jayanthi LD, Ramamoorthy S: Regulation of monoamine transporters: influence of psychostimulants and therapeutic antidepressants. AAPS J. 2005 Oct 27;7(3):E728-38. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16353949 # Verrico CD, Miller GM, Madras BK: MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl). 2007 Jan;189(4):489-503. Epub 2005 Oct 12. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16220332
n3:group
experimental illicit
n3:halfLife
6–10 (though duration of effects is typically actually 3–5 hours)
n3:indication
Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.
owl:sameAs
n15:DB01454 n17:DB01454
dcterms:title
3,4-Methylenedioxymethamphetamine
adms:identifier
n6:3%2C4-Methylenedioxymethamphetamine n7:PA131887008 n8:1615 n9:DB01454 n10:C07577 n11:1391 n12:1556 n13:46506404
n3:mechanismOfAction
It enters neurons via carriage by the monoamine transporters. Once inside, MDMA inhibits the vesicular monoamine transporter, which results in increased concentrations of serotonin, norepinephrine, and dopamine into the cytoplasm, and induces their release by reversing their respective transporters through a process known as phosphorylation. It also acts as a weak 5-HT1 and 5-HT2 receptor agonist. MDMA's unusual entactogenic effects have been hypothesized to be, at least partly, the result of indirect oxytocin secretion via activation of the serotonin system. Oxytocin is a hormone released following events like hugging, orgasm, and childbirth, and is thought to facilitate bonding and the establishment of trust. Based on studies in rats, MDMA is believed to cause the release of oxytocin, at least in part, by both directly and indirectly agonizing the serotonin 5-HT1A receptor.
n3:routeOfElimination
renal
n3:synonym
Ecstasy MDMA
n3:IUPAC-Name
n4:271B4C7C-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4C82-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4C81-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4C7E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4C7F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4C80-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4C7A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4C78-363D-11E5-9242-09173F13E4C5 n4:271B4C7B-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4C79-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4C88-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4C89-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4C83-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4C84-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4C86-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4C85-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4C87-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
42542-10-9
n3:Bioavailability
n4:271B4C8D-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4C8F-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4C90-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4C8C-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4C8B-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4C8E-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4C7D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4C8A-363D-11E5-9242-09173F13E4C5